SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Brain and vaccine vials
Alzheimer’s disease
New Wave of Alzheimer’s Therapies Actively Engage the Immune System
Active immune therapies hold promise for preventing or slowing disease onset, but some experts warn of potential safety risks.
August 5, 2024
 · 
5 min read
 · 
Gail Dutton
An empty hospital bed
Drug Development
Navigating Deaths During Clinical Trials
Fatalities are an unfortunate reality of clinical trials. How can companies best protect themselves?
July 29, 2024
 · 
6 min read
 · 
Gail Dutton
Psychiatric Drug Developers Make Recommendations Following Lykos Adcomm
Industry experts provide clinical trial design and protocol suggestions for psychedelic drug developers after an advisory committee voted against approving Lykos’ MDMA-assisted PTSD therapy.
June 27, 2024
 · 
7 min read
 · 
Gail Dutton
Pictured: A scale with DNA in the background
Drug Development
Genetic Therapies Show Early Promise in Treating Obesity
The plethora of genes involved in obesity presents an intriguing opportunity for both gene silencing and ex vivo gene therapy approaches.
June 14, 2024
 · 
5 min read
 · 
Gail Dutton
Pictured: A prescription bottle over a groovy neuro background
Policy
Lykos’ MDMA-Assisted Therapy Faces Landmark Adcomm
Experts say approval of Lykos Therapeutics’ MDMA capsules for post-traumatic stress disorder would open the door to further research into psychedelic-assisted therapies.
May 29, 2024
 · 
6 min read
 · 
Gail Dutton
Drug Development
Measuring Muscle Loss in the ‘Wild West’ of Weight Loss Drugs
The FDA currently does not recommend using changes in lean mass as an endpoint in clinical trials for weight loss drugs. Should it?
May 28, 2024
 · 
6 min read
 · 
Gail Dutton
Kitty Yale and Tim Rolph_Akero Therapeutics
Drug Development
GEN2 NASH Therapies Near the Finish Line
Industry leaders say the second generation of interventions for nonalcoholic steatohepatitis is likely to succeed where first-generation approaches stumbled.
February 6, 2023
 · 
4 min read
 · 
Gail Dutton
Courtesy of Getty Images
Does CRISPR Have a Bias Problem?
Recent scientific papers report errors in CRISPR gene editing linked to ancestry.
February 2, 2023
 · 
3 min read
 · 
Gail Dutton
Getty Images
Business
What Will it Take for AI to Live Up to its Hype?
The pharmaceutical industry is expected to spend more than $3 billion on artificial intelligence by 2025, but advocates say it is not yet living up to its potential.
January 30, 2023
 · 
4 min read
 · 
Gail Dutton
Andrea Izzotti/Shutterstock
Policy
Sen. Warren Leads Call for Prostate Cancer Drug Pricing Reform
A group of 25 senators, led by Sen. Elizabeth Warren (D-MA), is requesting that HHS Sec. Xavier Becerra exercise march-in rights for Xtandi (enzalutamide), a prostate cancer therapeutic.
January 24, 2023
 · 
5 min read
 · 
Gail Dutton
Courtesy of Getty Images
Deals
How to Prepare if Your Company is Being Acquired
If the letter of intent to acquire your company has been signed, you might be asking what happens next. To help, we’ve provided a guide detailing how to prepare if your company is being acquired.
January 16, 2023
 · 
5 min read
 · 
Gail Dutton
Courtesy of Getty Images
The Ins and Outs of Life Science Consulting, Explained by Experts
There are certain attributes one needs to be successful as a life science consultant. If you’re considering this career, check out our guide to learn the ins and outs of life science consulting.
January 16, 2023
 · 
7 min read
 · 
Gail Dutton
Mike Kemp/In PIctures via Getty Images
Executives Reunite at JPM as Biotech Kicks Off 2023
JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.
January 4, 2023
 · 
5 min read
 · 
Gail Dutton
Unity CEO Anirvan Ghosh, Ph.D./courtesy of Unity B
Drug Development
Senolytic Therapies Pose Revolutionary Potential to Roll Back Diseases of Aging
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.
December 14, 2022
 · 
6 min read
 · 
Gail Dutton
Drug Development
Novel Capabilities of Innovative AntibodyPlus Therapeutics Go Beyond ADCs
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
December 13, 2022
 · 
7 min read
 · 
Gail Dutton
Load More